ESOP/ESOS/ESPS
டீல்
டீல் மதிப்பு₹6 கோடி
டீல் vs வணிகம்Land LOI = ₹6.21 Cr (~2.2% of TTM revenue ₹278 Cr)
சொந்த வருவாயுடன் ஒப்பிடும் அளவு0.02×
செயல்படுத்தும் காலம்2.0 ஆண்டு
அடிப்படை தரம்B
AI முன்கணிப்புகள்
வருவாய் உயர்வு (முதல் ஆண்டு / நிலையான)0.0% / 12.5%
EPS உயர்வு13.0%
அப்சைடு பேஸ் / புல் / பேர்35.0% / 75.0% / -25.0%
கால எல்லை24-36 மாதங்கள்
உண்மையான சந்தைப் பதிவு
நுழைவு — அடுத்த நாள் தொடக்கம் (12 ஆக. 2026)₹213.0
சமீபத்திய முடிவு விலை (12 நவ. 2026)₹206.56
தொடங்கியதிலிருந்து வருமானம்-3.0%
α vs Smallcap 250-0.4%
α vs சொந்தத் துறை+4.5% (ஹெல்த்கேர் இடைநிலை -4.9%, 55 முதிர்ந்த தேர்வுகளின் அடிப்படையில்)
நேர்மறைகள்
- Market leadership as India's largest export dental laboratory and the second-largest domestic dental laboratory player.
- Fast digital dentistry adoption with intra-oral scanner sales up 94.7% YoY acting as a recurring high-margin aligner and crown volume hook.
- Robust balance sheet with D/E of 0.04 (Debt ₹11 Cr vs Net Worth ₹247 Cr) supported by ₹64 Cr unutilized IPO proceeds for expansion.
- Solid organic topline momentum with FY26 revenue rising 25.8% YoY to ₹278 Cr and double-digit growth across dental lab and aligner divisions.
அபாயங்கள்
- Catalyst is at preliminary LOI stage for land acquisition (₹6.21 Cr), generating zero revenue in the first 12-18 months.
- Margin vulnerability to US tariffs and trade barriers (caused ~90 bps drag in H1 FY26) given international sales represent ~45% of core revenue.
- Trailing valuation at 40.0x P/E requires sustained 20%+ EPS growth with limited margin for execution delays.
- Moderate trailing ROCE of 12.0% reflects ongoing investment phase in digital workflows and brand building.
முழு AI சுருக்கம்
1. Ramp-Aware Catalyst & Impact Analysis
- Announcement Details: Laxmi Dental signed a Letter of Intent (LOI) to acquire industrial land in Palghar, Maharashtra for ₹6.21 Cr and allotted 59,360 ESOP shares.
- Relative Size: The ₹6.21 Cr land deal equals 2.23% of TTM revenue (₹278 Cr) and 2.51% of Net Worth (₹247 Cr). This is a routine early-stage infrastructure acquisition, not a mega-contract.
- Execution Schedule: Land closing, civil construction, and cleanroom/machinery installation will require 18-24 months.
- Year-1 Revenue Impact: 0.0% (construction phase).
- Steady-State Potential: Utilizing existing unutilized IPO funds (~₹64 Cr) on this land parcel could eventually house ₹35-40 Cr in incremental annual processing capacity (+12.5% on TTM revenue).
- Earnings Impact: At an estimated 16% OPM and 11% NPM, incremental PAT would be ~₹4.0 Cr, delivering ~13% EPS expansion by FY29.
2. தொழில்துறைச் சூழல் & மூலதனத் தீவிரம்
- Sector: Healthcare / Dental Devices and Prosthetics.
- Capital Intensity: Medium. Requires precision milling machines, 3D printers, and digital design setups.
- Industry Growth: Domestic and global dental prosthetics and clear aligners are expanding at an estimated 18% CAGR, fueled by digital scanning adoption, aesthetic consciousness, and lab consolidation.
3. Fundamental Quality & SEPA Checklist
- Topline Momentum: FY26 revenue grew 25.8% YoY to ₹278 Cr (Q4 FY26 grew 21.9% YoY to ₹74 Cr).
- Profitability & Margins: FY26 OPM was 15.8% and NPM was 10.4% (PAT ₹29 Cr). Pricing power demonstrated in aligners (margins expanded from 6.8% to 15.8%).
- Financial Health: Debt is minimal at ₹11 Cr (D/E 0.04), with ₹247 Cr net worth and ample liquidity from IPO proceeds.
- ROCE: 12.0%, constrained by initial digital infrastructure rollouts but showing operating leverage potential.
- Ownership: Promoter holding stands stable at 41.8%.
4. Valuation & Multi-Scenario Return Calibrations (24-36 Months)
- Current Base: Price ₹210.8, Market Cap ₹1,160 Cr, TTM EPS ₹5.27, Trailing P/E 40.0x.
- Bull Case (+75%): 25% revenue CAGR driven by US FDA approvals and accelerated aligner volume, reaching ~₹435 Cr by FY28 with 13.5% NPM (PAT ₹58.7 Cr, EPS ₹10.67). Target P/E 35x yields ₹370/share.
- Base Case (+35%): 20% revenue CAGR reaching ~₹400 Cr by FY28 with 11% NPM (PAT ₹44.0 Cr, EPS ₹8.00). Target P/E 35x yields ₹285/share.
- Bear Case (-25%): Revenue slows to 10% on trade tariff friction and scanner adoption delays; NPM compresses to 9.0% (PAT ₹31.0 Cr, EPS ₹5.63). De-rating to 28x P/E yields ₹158/share.
5. தீர்ப்பின் காரணம்
Laxmi Dental is a high-quality niche market player in digital dentistry and aligners. While the land LOI announcement is fundamentally small and low-impact in the immediate term (Score 25), the underlying business displays solid compounding traits. Verdict is POSSIBLE with a multibagger score of 52.
2026-08-11 நிலவரப்படி பகுப்பாய்வு (விலை ₹210.76) · AI ஆய்வு, முதலீட்டு ஆலோசனை அல்ல.
பின்தொடர்Telegram
